{"entity":{"id":"nct07582432","kind":"trial","name":"A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma","aka":[],"tldr":"A phase 3 trial of Gamunex-C, 10% Injectable Solution in non-Hodgkin lymphoma, run by Grifols Biologicals, LLC, now recruiting.","summary":"A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma is a phase 3 interventional study registered as NCT07582432 by Grifols Biologicals, LLC, with 49 participants planned, started 2026-04-23 and due to reach its primary completion in 2028-08-31. Interventions recorded: Gamunex-C, 10% Injectable Solution.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07582432","url":"https://clinicaltrials.gov/study/NCT07582432"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["grifols"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07582432","phase":"3","setting":"An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C Plus Standard Medical Treatment to Prevent Infections in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma","sponsor":"Grifols Biologicals, LLC","enrolled":49,"outcomes":[]},"route":"/trials/nct07582432/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"grifols","kind":"company","name":"Grifols","route":"/companies/grifols/"}]}}